IPO
SkinBioTherapeutics plc, a life sciences company focused on skin health, announces changes to its Board and executive team and provides a business update.
The early-stage biotech company, previously named FLX Bio, plans to raise up to $86 million with the IPO. It plans to trade on the Nasdaq under the ticker symbol RAPT.
Hutchison China MediTech Limited will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm Hong Kong Time (HKT); 2:00 am Eastern Daylight Time (EDT)).
Fusion Antibodies plc announces its final results for the year ended 31 March 2019.
BioArctic AB to publish the company’s Interim Report for the period January – June 2019 on Thursday, July 11, 2019 at 08:00 a.m. CET.
EIB and German specialty pharmaceutical company PAION AG have signed a EUR 20 million loan agreement
The European Investment Bank will lend up to €20 million to PAION AG, a German pharmaceutical company specialised in anaesthesia and sedation drugs.
The company is working on developing therapies for neuropsychiatric diseases. Karuna is expecting data from a Phase II clinical trial later this year of KarXT xanomeline/trospium chloride, a muscarinic receptor modulator, to treat acute psychosis associated with schizophrenia.
BridgeBio Pharma, Inc. has announced the pricing of its initial public offering of 20,500,000 shares of its common stock at a price to the public of $17.00 per share, as detailed in the company’s press release.
Velabs Therapeutics GmbH announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options.
NOXXON Pharma N.V. announced that the annual general shareholders meeting held on Tuesday, June 25, 2019 at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, the Netherlands approved all voting items.
PRESS RELEASES